Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

Fiche publication

Date publication

août 2026

Journal

Liver international : official journal of the International Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher

Tous les auteurs :
Liguori C, Giampieri R, Delaunay B, Pinterpe G, Mazzocca A, Hollebecque A, Blanc JF, Bouattour M, Assenat E, Abdelghani MB, Sarabi M, Niger M, Vivaldi C, Mandalà M, Palloni A, Bensi M, Garattini SK, Tougeron D, Combe P, Salati M, Rimini M, Casadei-Gardini A, Cella CA, Tucci M, Diana A, Mori E, Longarini R, Artru P, Roth G, Evesque L, Vienne A, Turpin A, Hiret S, Bourgeois V, Herve C, Paulon R, Stacoffe M, Malka D, Delaye M, Edeline J, Lievre A, Guimbaud R, Balsano R, Fares N, Berardi R, Parisi A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42494243

Résumé

Anti-FGFR therapies changed the treatment landscape for patients with previously treated, advanced, or metastatic cholangiocarcinoma (CCA) harbouring FGFR2 fusions/rearrangements. However, primary resistance to FGFR inhibitors remains a key challenge. In the present real-world study, we aimed to evaluate the prognostic impact of concomitant GAs in patients with FGFR2-positive CCA treated with pemigatinib.